Baird analyst Joel Beatty lowered the firm’s price target on Neurogene (NGNE) to $38 from $46 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results which showed ita registrational trial design update is on track for the first half of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks